US: Major Legal Battle Over Abortion Pill Mifepristone Telemedicine Access in Federal Court
The Fifth Circuit Court of Appeals hears challenges against FDA rules allowing mail delivery and telehealth prescriptions of mifepristone.
Washington: The high-stakes legal battle surrounding access to the widely used abortion medication mifepristone has intensified before the US Fifth Circuit Court of Appeals. The State of Louisiana is challenging federal FDA regulations from 2023 that allow patients to consult physicians via telehealth and receive mifepristone by mail.
Judges expressed skepticism over the state's standing and claims, noting medication abortion currently accounts for over 60% of all pregnancy terminations across the United States. Meanwhile, lawmakers in Congress re-introduced legislation aimed at codifying FDA regulatory supremacy.
About Health Desk
Health Desk is a senior correspondent at Greenline News covering health and related global events.
View all articles by Health DeskComments (2)
Excellent reporting on this issue. It's crucial that we stay informed about these developments.
I wonder how this will affect the local communities in the long run. Would love to see a follow-up article.